Financials data is unavailable for this security.
View more
Year on year Hansoh Pharmaceutical Group Company Ltd grew revenues 7.69% from 9.38bn to 10.10bn while net income improved 26.85% from 2.58bn to 3.28bn.
| Gross margin | 91.01% |
|---|---|
| Net profit margin | 38.97% |
| Operating margin | 45.06% |
| Return on assets | 14.82% |
|---|---|
| Return on equity | 18.10% |
| Return on investment | 17.87% |
More ▼
Cash flow in CNYView more
In 2023, Hansoh Pharmaceutical Group Company Ltd increased its cash reserves by 124.31%, or 3.31bn. The company earned 3.12bn from its operations for a Cash Flow Margin of 30.84%. In addition the company generated 1.07bn cash from investing, though they paid out 753.70m more in financing than they received.
| Cash flow per share | 0.913 |
|---|---|
| Price/Cash flow per share | 19.28 |
| Book value per share | 5.06 |
|---|---|
| Tangible book value per share | 5.02 |
More ▼
Balance sheet in CNYView more
| Current ratio | 7.98 |
|---|---|
| Quick ratio | 7.81 |
| Total debt/total equity | 0.0043 |
|---|---|
| Total debt/total capital | 0.0043 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 119.11% and 24.95%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | -- |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 24.45% |
| EPS growth(5 years) | 8.11 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 81.07 |
More ▼
